{
  "x402Version": 2,
  "id": 4546,
  "slug": "4546",
  "resource": "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal",
  "description": "Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.",
  "type": "http",
  "accepts": [
    {
      "scheme": "exact",
      "network": "eip155:8453",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:8453",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "amount": "350000",
      "maxTimeoutSeconds": 604900
    },
    {
      "scheme": "exact",
      "network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
      "payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
      "asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:137",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:42161",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0xaf88d065e77c8cC2239327C5EDb3A432268e5831",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:480",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x79A02482A880bCe3F13E09da970dC34dB4cD24D1",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:143",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x754704Bc059F8C67012fEd69BC8A327a5aafb603",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:196",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x779ded0c9e1022225f8e0630b35a9b54be713736",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:999",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0xb88339CB7199b77E23DB6E890353E22632Ba630f",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k",
      "payTo": "62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I",
      "asset": "31566704",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "xrpl:0",
      "payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
      "asset": "XRP",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "xrpl:0",
      "payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
      "asset": "524C555344000000000000000000000000000000",
      "amount": "0.35",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:56",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d",
      "amount": "350000000000000000",
      "maxTimeoutSeconds": 300
    }
  ],
  "outputSchema": {
    "bazaar": {
      "info": {
        "input": {
          "method": "GET",
          "queryParams": {
            "condition": "Disease area — e.g. \"Obesity\" | \"Cardiovascular\" | \"Oncology\" | \"Rare Neurological\" | \"Autoimmune\"",
            "deal_type": "acquisition | licensing | both (default: both)",
            "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
            "stage": "phase2 | phase3 | both (default: both)"
          },
          "type": "http"
        },
        "output": {
          "example": {
            "acquisition_targets": [
              {
                "asset": "Mazdutide (IBI362)",
                "clinical_data": "Phase 3 China data strong — 14.5% body weight reduction at 52 weeks",
                "company": "Innovent Biologics (China)",
                "deal_comp": "Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.",
                "deal_rationale": "Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.",
                "estimated_deal_value_usd_m": "800-2000",
                "mechanism": "GLP-1/glucagon dual agonist",
                "probability": "High",
                "risks": [
                  "China geopolitical risk for IP transfer",
                  "Phase 3 US/EU data needed before deal close"
                ],
                "stage": "PHASE3"
              }
            ],
            "deal_timing_signals": "Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.",
            "licensing_opportunities": [
              {
                "asset": "CT-388 (dual GLP-1/GIP)",
                "company": "Carmot Therapeutics (acq. Roche)",
                "estimated_license_value_usd_m": "300-800",
                "notes": "Roche may sublicense ex-US rights to regional partners in Asia/LatAm"
              }
            ],
            "market_context": {
              "approved_leaders": [
                "Semaglutide (Novo Nordisk — Wegovy)",
                "Tirzepatide (Lilly — Zepbound)"
              ],
              "big_pharma_strategic_need": "Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.",
              "total_addressable_market_usd_bn": 100
            },
            "query_summary": {
              "as_of": "2026-06-07",
              "condition": "Obesity",
              "deal_type": "both",
              "stage": "both"
            },
            "recent_deal_comps": [
              {
                "deal": "Roche / Carmot Therapeutics",
                "mechanism": "GLP-1 peptide",
                "stage": "PHASE1/2",
                "value_usd_bn": 2.7,
                "year": 2023
              },
              {
                "deal": "AstraZeneca / Eccogene",
                "mechanism": "Small-molecule GLP-1",
                "stage": "PHASE2",
                "value_usd_bn": 1.85,
                "year": 2024
              },
              {
                "deal": "Amgen / ChemoCentryx",
                "mechanism": "C5aR1",
                "stage": "Approved",
                "value_usd_bn": 3.7,
                "year": 2022
              }
            ]
          },
          "type": "json"
        }
      },
      "schema": {
        "$schema": "https://json-schema.org/draft/2020-12/schema",
        "properties": {
          "input": {
            "additionalProperties": false,
            "properties": {
              "method": {
                "enum": [
                  "GET",
                  "HEAD",
                  "DELETE"
                ],
                "type": "string"
              },
              "queryParams": {
                "properties": {
                  "condition": {
                    "type": "string"
                  },
                  "deal_type": {
                    "type": "string"
                  },
                  "lang": {
                    "type": "string"
                  },
                  "stage": {
                    "type": "string"
                  }
                },
                "type": "object"
              },
              "type": {
                "const": "http",
                "type": "string"
              }
            },
            "required": [
              "type",
              "method"
            ],
            "type": "object"
          },
          "output": {
            "properties": {
              "example": {
                "type": "object"
              },
              "type": {
                "type": "string"
              }
            },
            "required": [
              "type"
            ],
            "type": "object"
          }
        },
        "required": [
          "input"
        ],
        "type": "object"
      }
    },
    "builder-code": {
      "info": {
        "a": "bc_gxy6qn5p"
      },
      "schema": {
        "$schema": "https://json-schema.org/draft/2020-12/schema",
        "additionalProperties": false,
        "properties": {
          "a": {
            "description": "App builder code",
            "pattern": "^[a-z0-9_]{1,32}$",
            "type": "string"
          },
          "s": {
            "description": "Service builder codes",
            "items": {
              "pattern": "^[a-z0-9_]{1,32}$",
              "type": "string"
            },
            "type": "array"
          },
          "w": {
            "description": "Wallet builder code",
            "pattern": "^[a-z0-9_]{1,32}$",
            "type": "string"
          }
        },
        "type": "object"
      }
    }
  },
  "tags": [
    "bazaar",
    "builder-code"
  ],
  "sourceHost": "clinicalintelpulse.theaslangroupllc.com",
  "lastUpdated": "2026-08-20T14:01:57.877Z",
  "quality": {
    "calls30d": 1,
    "uniquePayers30d": 1,
    "lastCalledAt": "2026-08-20T14:01:57.673Z"
  },
  "liveness": {},
  "verified": false,
  "featured": false,
  "provider": {
    "host": "clinicalintelpulse.theaslangroupllc.com",
    "manifest_name": "clinicalintelpulse.theaslangroupllc.com",
    "source": "cdp-mirror",
    "source_manifest_url": "https://api.cdp.coinbase.com/platform/v2/x402/discovery/resources",
    "submitted_at": "2026-09-18T22:00:31.484Z"
  }
}